KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $76.1 million.

  • West Pharmaceutical Services' Capital Expenditures fell 2745.47% to $76.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $285.9 million, marking a year-over-year decrease of 2416.45%. This contributed to the annual value of $285.9 million for FY2025, which is 2416.45% down from last year.
  • West Pharmaceutical Services' Capital Expenditures amounted to $76.1 million in Q4 2025, which was down 2745.47% from $63.3 million recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' Capital Expenditures registered a high of $108.7 million during Q4 2023, and its lowest value of $54.7 million during Q1 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $75.8 million (2023), whereas its average is $78.1 million.
  • In the last 5 years, West Pharmaceutical Services' Capital Expenditures skyrocketed by 7040.5% in 2021 and then tumbled by 2745.47% in 2025.
  • West Pharmaceutical Services' Capital Expenditures (Quarter) stood at $76.5 million in 2021, then grew by 24.05% to $94.9 million in 2022, then rose by 14.54% to $108.7 million in 2023, then decreased by 3.5% to $104.9 million in 2024, then decreased by 27.45% to $76.1 million in 2025.
  • Its Capital Expenditures stands at $76.1 million for Q4 2025, versus $63.3 million for Q3 2025 and $75.2 million for Q2 2025.